21.3 C
New York
Friday, June 5, 2026

Tag: fatigue

newssourceFORcompanyinformationcontent1marketreleases

Osara Health Expands Into Survivorship Care, Strengthening Cancer Support Beyond Treatment

The expanded Cancer Coach program introduces new survivorship modules building on the latest outcomes showing a 25:1 ROI and ~66% of participants improved physical...

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).

In HelloNation, Holistic Health Expert Cynde Schneider Discusses How Integrative Medicine Differs From Traditional Medical Care

LAMESA, Texas, June 3, 2026 /PRNewswire/ -- The article explores how personalized care and lifestyle-focused evaluations support long-term overall wellness. ...

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults

AQUIPTA® (atogepant) is now approved in the European Union for the acute treatment of migraine in adults, with or without aura, and for the...

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement adds to the adult marketing authorization already received in Canada1 and complements the adolescent label extension received in Europe in April 20252.

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years

Aira Health Unveils Innovative Wellness Solutions for Women’s Health

Introducing Aira Health: Thoughtfully Formulated Supplements for Women’s Wellness 
Introducing Aira Health: Thoughtfully Formulated Supplements for Women’s Wellness

From Everyday to Extreme, toolant Launches Brand New Line of Hand Tools

This innovative collection includes a brand new cost-performance plier wrench as well as best-selling compact flex-head ratchet for tight spaces to revolutionize your toolbox 
This innovative collection includes a brand new cost-performance plier wrench as well as best-selling compact flex-head ratchet for tight spaces to revolutionize your toolbox

Best Ergonomic Office Chair for Long Hours (2025): FlexiSpot C7 Max Recognized as Top Comfort & Support Choice by Expert Consumers

NEW YORK, Aug. 15, 2025 /PRNewswire/ -- Expert Consumers has recognized the FlexiSpot C7 Max as the Best Ergonomic Office Chair for Long Hours...

Young Mother’s Battle with Arthritis Highlights Need for Timely Access to Modern Medications in BC

VANCOUVER, BC, Aug. 14, 2025 /CNW/ - Eileen Davidson, a Burnaby mother and advocate, is calling on the BC government to modernize its approach to...

Wong To Yick Wood Lock Medicated Balm Proudly Announces Cantopop Diva Joey Yung as Its First-Ever Brand Ambassador

"No.1 Meets No.1" – A Legendary Collaboration Redefining Excellence HONG KONG, Aug. 13, 2025 /PRNewswire/ -- Renowned Hong Kong heritage brand Wong To Yick Wood...

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late...

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFatigue

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers